Sun Zhipeng, Hong Baoan, Wang Yuxuan, Zhang Xuezhou, Wang Wei, Miao Qi, Li Mingchuan, Bo Yuxuan, Zhang Ning
Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Transl Androl Urol. 2025 Jun 30;14(6):1503-1519. doi: 10.21037/tau-2025-89. Epub 2025 Jun 19.
BACKGROUND: Adrenal vein sampling (AVS) is the gold standard for diagnosing the dominant side in patients with primary aldosteronism (PA). encodes aldosterone synthase. The aim of this study was to investigate the prognosis of dominant-side adrenalectomy in patients with PA identified by AVS in the context of aldosterone synthase expression in the postoperative pathology of those patients. METHODS: This retrospective study included 73 PA patients who underwent AVS followed by unilateral adrenalectomy. Patients were categorized into AVS bilateral success group, AVS unilateral success group, and AVS bilateral failure group based on their AVS status. Immunohistochemistry (IHC) for CYP11B2 was combined with postoperative pathology in these patients, and the clinical and biochemical prognosis of these patients was assessed 6 months after adrenalectomy. RESULTS: Between September 2023 and September 2024, 73 patients underwent unilateral adrenalectomy guided by AVS at our institution, with CYP11B2 IHC successfully performed in 63 cases. Among these, 21 patients (33.33%) achieved bilateral AVS success, 20 (31.75%) demonstrated unilateral AVS success, and 22 (34.92%) exhibited bilateral AVS failure. Pathological analysis of the bilateral AVS success group revealed aldosterone-producing adenoma (APA) in 12 cases, aldosterone-producing micronodule (APM) in 1, multiple-aldosterone-producing micronodules/nodules (MAPM/MAPN) in 2, aldosterone-producing diffuse hyperplasia (APDH) in 1, APA with MAPM in 3, and APA with APDH in 2. In this group, complete and partial clinical success rates were 47.62% (10/21) and 52.38% (11/21), respectively, while biochemical success rates reached 95.24% (20/21) for complete and 4.76% (1/21) for partial success. The unilateral AVS success cohort included APA (n=8), aldosterone-producing nodule (APN) (n=2), MAPM/MAPN (n=3), APA with MAPM (n=4), APA with APDH (n=2), and 1 CYP11B2 IHC-negative lesion, with clinical success rates of 40.00% (8/20) complete and 60.00% (12/20) partial, alongside 90.00% (18/20) complete and 10.00% (2/20) partial biochemical success. The bilateral AVS failure group comprised APA (n=8), MAPM/MAPN (n=1), APA with MAPM (n=5), APA with APDH (n=2), and 6 CYP11B2 IHC-negative lesions, demonstrating 36.36% (8/22) complete, 50.00% (11/22) partial, and 13.64% (3/22) no clinical success, with biochemical outcomes of 72.73% (16/22) complete, 18.18% (4/22) partial, and 9.09% (2/22) no success. Notably, bilateral AVS success correlated with significantly superior biochemical outcomes compared to bilateral failure (P=0.045). CONCLUSIONS: Adrenalectomy guided by AVS yields better outcomes in patients with PA when AVS is successful on both sides compared to those with bilateral AVS failure. The source of excess aldosterone secretion on the dominant side identified by AVS is not necessarily an APA/APN. It may also include MAPM/MAPN, diffuse adrenal cortical hyperplasia, and various complex combined conditions. In patients with bilateral AVS failure, adrenal specimens more frequently exhibit negative immunohistochemical staining for CYP11B2.
背景:肾上腺静脉采血(AVS)是诊断原发性醛固酮增多症(PA)患者优势侧的金标准。编码醛固酮合酶。本研究的目的是在PA患者术后病理中醛固酮合酶表达的背景下,探讨经AVS确定优势侧的肾上腺切除术患者的预后。 方法:这项回顾性研究纳入了73例行AVS后接受单侧肾上腺切除术的PA患者。根据AVS情况,将患者分为AVS双侧成功组、AVS单侧成功组和AVS双侧失败组。对这些患者进行CYP11B2免疫组织化学(IHC)检查并结合术后病理,在肾上腺切除术后6个月评估这些患者的临床和生化预后。 结果:2023年9月至2024年9月,我院73例患者在AVS引导下接受了单侧肾上腺切除术,其中63例成功进行了CYP11B2 IHC检查。其中,21例(33.33%)实现双侧AVS成功,20例(31.75%)表现为单侧AVS成功,22例(34.92%)出现双侧AVS失败。双侧AVS成功组的病理分析显示,12例为醛固酮瘤(APA),1例为醛固酮生成微结节(APM),2例为多发性醛固酮生成微结节/结节(MAPM/MAPN),1例为醛固酮生成弥漫性增生(APDH),3例为APA合并MAPM,2例为APA合并APDH。该组完全和部分临床成功率分别为47.62%(10/21)和52.38%(11/21),而生化成功率完全成功为95.24%(20/21),部分成功为4.76%(1/21)。单侧AVS成功队列包括APA(n = 8)、醛固酮生成结节(APN)(n = 2)、MAPM/MAPN(n = 3)、APA合并MAPM(n = 4)、APA合并APDH(n = 2)以及1例CYP11B2 IHC阴性病变,临床成功率完全成功为40.00%(8/20),部分成功为60.00%(12/20),生化成功率完全成功为90.00%(18/20),部分成功为10.00%(2/20)。双侧AVS失败组包括APA(n = 8)、MAPM/MAPN(n = 1)、APA合并MAPM(n = 5)、APA合并APDH(n = 2)以及6例CYP11B2 IHC阴性病变,完全临床成功率为36.36%(8/22),部分临床成功率为50.00%(11/22),无临床成功率为13.64%(3/22),生化结果为完全成功72.73%(16/22),部分成功18.18%(4/22),无成功9.09%(2/22)。值得注意的是,与双侧失败相比,双侧AVS成功与显著更好的生化结果相关(P = 0.045)。 结论:与双侧AVS失败的患者相比,AVS引导下的肾上腺切除术在双侧AVS成功的PA患者中产生更好的结果。AVS确定的优势侧过量醛固酮分泌的来源不一定是APA/APN。它还可能包括MAPM/MAPN、弥漫性肾上腺皮质增生以及各种复杂的合并情况。在双侧AVS失败的患者中,肾上腺标本更频繁地表现出CYP11B2免疫组织化学染色阴性。
Cardiovasc Intervent Radiol. 2025-7
J Endocrinol Invest. 2025-3-15
Front Endocrinol (Lausanne). 2024
J Endocrinol. 2023-9-1
J Clin Endocrinol Metab. 2023-12-21
Zhonghua Nei Ke Za Zhi. 2022-10-1
Nat Rev Endocrinol. 2022-11